Research progress on adjuvant transcatheter arterial chemoembolization in postoperative hepatocellular carcinoma
LI Jinghe SHI Zhengrong
Liver Transplantation Center, Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Abstract：Transcatheter arterial chemoembolization (TACE) has become an important adjuvant therapy in postoperat -ive hepatocellular carcinoma, and the effect of TACE has gradually gained the attention of clinicians. The current study suggests that recurrence after hepatocellular carcinoma resection is related to the failure to detect potential microscopic lesions in time. Since the blood supply to liver cancer tissue is mainly derived from the hepatic artery, the adjuvant use of TACE can lead to tumor tissue ischemia and necrosis in the embolization area, which can help eliminate small residual cancer, and theoretically can reduce recurrence and prolong survival. However, the actual clinical efficacy and scope of application are still the focus of current explore and research. In this paper, the application opportunity, the applicable population, the application mode and the research progress of efficacy detection of TACE are described.
[1] Wang FS，Fan JG，Zhang Z，et al. The global burden of liver disease： the major impact of China [J]. Hepatology，2014，60（6）：2099-2108.
[2] Yim HJ，Suh SJ，Um SH. Current management of hepatocellular carcinoma：An Eastern perspective [J]. World J Gastroenterol，2015，21（13）：3826-3842.
[3] 张能平，丁佑铭.肝细胞性肝癌手术治疗的疗效及影响因素的分析[J].实用癌症杂志，2017，32（1）：112-114.
[4] 朱轲.介入治疗与常规化疗对中晚期原发性肝癌患者的影响分析[J].临床研究，2018，26（11）：78-79.
[5] 王建斌，梁栋，王全楚.原发性肝癌的非手术治疗[J].胃肠病学和肝病学杂志，2019，28（2）：126-128.
[6] Sun J，Yang L，Shi J，et al. Postoperative adjuvant IMRT for patients with HCC and portal vein tumor thrombus： An open-label randomized controlled trial [J]. Radiother Oncol，2019，140：20-25.
[7] Jianyong L，Jinjing Z，Wentao W，et al. Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma：a single center analysis [J]. Ann Hepatol，2014，13（4）：394-402.
[8] 荣维淇，余微波，吴凡，等.术前介入治疗对肝细胞癌患者围手术期转归的影响[J].中华肿瘤杂志，2015，37（9）：671-675.
[9] Tao Q，He W，Li B，et al. Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence [J]. J Cancer，2018，9（16）：2778-2785.
[10] Xie H，Tian S，Cui L，et al. Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma [J]. Cancer Manag Res，2019，11：4065-4073.
[11] Ye JZ，Chen JZ，Li ZH，et al. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion [J]. World J Gastroenterol，2017，23（41）：7415-7424.
[12] Wang YY，Wang LJ，Xu D，et al. Postoperative adjuvant transcatheter arterial chemoembolization should be considered selectively in patients who have hepatocellular carcinoma with microvascular invasion [J]. HPB（Oxford），2019，21（4）：425-433.
[13] Gao Z，Du G，Pang Y，et al. Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors [J]. Medicine（Baltimore），2017，96（33）：e7426.
[14] Lazuardi F，Valencia J，Zheng S. Adjuvant transcatheter arterial chemoembolization after radical resection of hepatocellular carcinoma patients with tumor size less than 5 cm：a retrospective study [J]. Scand J Gastroenterol，2019，54（5）：617-622.
[15] 黄书明，陈圣开，张涛.肝癌切除术联合术后TACE对肝癌合并门静脉癌栓患者的治疗效果及预后影响因素分析[J].中国医学前沿杂志：电子版，2016，8（6）：160-164.
[16] 刘亚楠. TACE术对肝癌肝切除术后早期复发的影响[D].郑州：郑州大学，2019.
[17] Zhang XP，Liu YC，Chen ZH，et al. Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion： A Propensity Score Matching Analysis [J]. Ann Surg Oncol，2019，26（5）：1465-1473.
[18] Kloeckner R，Weinmann A，Prinz F，et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma [J]. BMC Cancer，2015，15：465.
[19] Liu YS，Lin CY，Chuang MT，et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma [J]. BMC Gastroenterol，2018，18（1）：124.
[20] 陈慧华，文玲波，李建安，等.恩替卡韦联合肝动脉化疗栓塞术治疗乙肝相关性肝癌临床效果的Meta分析[J].中国医药导报，2017，14（29）：93-97.
[21] 辛梦，冯东峰，殷蓓蓓，等.乙型肝炎病毒相关性肝癌TACE术后干扰素治疗临床观察[J].中华肿瘤防治杂志，2018，25（9）：652-658.
[22] Zhu Y，Cui PJ，Yao J，et al. Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy [J]. Gastroenterol Res Pract，2018，2018：6 414 759.
[23] Chen XX，Cheng JW，Huang A，et al. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection：a systematic review and meta-analysis [J]. Onco Targets Ther，2017，10：5363-5375.
[24] Li J，Hou Y，Cai XB，et al. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma [J]. World J Gastroenterol，2016，22（15）：4034-4040.
[25] 王春艳，吴斌，兰川，等.经导管肝动脉化疗栓塞术联合索拉非尼治疗晚期肝细胞癌的效果[J].中国医药导报，2017，14（14）：77-79.
[26] 张洪海，孙玉，生守鹏，等.乙肝相关肝癌射频消融术后复发因素分析[J].北京医学，2019，41（6）：468-471，475.
[27] 沈迪，张莉，金恩浩，等.甲胎蛋白对原发性肝癌患者TACE治疗效果及预后的评估价值[J].实用癌症杂志，2019，34（4）：640-643.
[28] Shalimar，Jain S，Gamanagatti SR，et al. Role of Indocyanine Green in Predicting Post-Transarterial Chemoembolization Liver Failure in Hepatocellular Carcinoma [J]. J Clin Exp Hepatol，2018，8（1）：28-34.
[29] 谢青云，雷泽华，高峰畏，等.原发性肝癌TACE介入治疗前后血清AFP、AKP、γ-GT水平的变化[J].昆明医科大学学报，2018，39（10）：101-104.
[30] 李红学，刘军杰，胡巧琴，等.超声造影在肝癌TACE术后残留诊治中的价值[J].医学研究杂志，2018，47（10）：57-60.
2020, Vol. 17 
京公网安备 11010502046598号